National Medical Products Administration (NMPA) approves deuremidevir
(VV116) and simnotrelvir-ritonavir for mild to moderate COVID-19 in
China.
- Ke-Wei Zhu
Ke-Wei Zhu
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Corresponding Author:zhukew2018@outlook.com
Author Profile
